Hansoh Pharmaceutical Group Company Limited has announced a significant licensing agreement with Regeneron Pharmaceuticals, Inc. The agreement grants Regeneron an exclusive worldwide license, excluding the Chinese Mainland, Hong Kong, and Macau, to develop, manufacture, and commercialize HS-20094, an investigational dual GLP-1/GIP receptor agonist. The licensure will see Hansoh receiving an upfront payment of $80 million, with the potential for up to $1.93 billion in milestone payments tied to the product's development, regulatory approval, and commercialization. Additionally, Hansoh will earn double-digit royalties from potential future product sales. HS-20094 has completed multiple Phase II trials with positive results and is currently undergoing a Phase III clinical trial in China. This collaboration marks a strategic advancement for both companies in the biotechnology sector.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.